Trial Profile

Phase III study of istaroxime for acute heart failure

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 24 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jan 2024 According to Windtree Therapeutics media release, the company has entered into a license agreement with Lees Pharmaceutical (HK) Limited for the development and commercialization of Windtrees product candidate istaroxime in Greater China
17 Jan 2024 According to Windtree Therapeutics media release, Lees plans to initiate and fund Phase 3 for istaroxime in acute heart failure in Greater China
28 Sep 2022 According to a Windtree Therapeutics media release, the company look forward to meet with the FDA to discuss the potential Phase 3 program.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com